Short-acting beta-agonist (SABA) over-use in asthma is harmful for patients and the environment. The Investment and Impact Fund (IIF) 2022/2023 financially rewarded English primary care networks that achieved specific targets, including reducing SABA over-use (RESP-02) and lowering the mean carbon footprint per salbutamol inhaler prescribed (ES-02). SENTINEL Plus is a co-designed quality improvement package that aims to improve asthma outcomes and reduce asthma's environmental impact by addressing SABA over-use. We investigated the impact of (i) the IIF incentives and (ii) SENTINEL Plus implementation on asthma prescribing. Using Openprescribing.net data, we demonstrate that IIF 2022-2023 had no significant impact on the total number of SABA prescribed in England (25,927,252 during 12-months pre- and 25,885,213 12-months post-IIF; 0.16% decrease; p=NS), but lower carbon footprint SABA inhaler use increased (Salamol™ prescribing increased from 5.1% to 19% of SABA prescriptions, p < 0.01). In contrast, SENTINEL Plus sites significantly reduced SABA prescribing post-implementation (5.43% decrease, p < 0.05).
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11058200 | PMC |
| http://dx.doi.org/10.1038/s41533-024-00363-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Reliever Reliance Test: evaluating a new tool to address SABA over-reliance.
NPJ Prim Care Respir Med
November 2024
Centre for Behavioural Medicine, University College London, London, UK.
Article Synopsis
- Over-reliance on Short-Acting Beta-Agonists (SABA) leads to poor asthma control and increased risks of exacerbations and death, highlighting the need for intervention.
- The study evaluated the Reliever Reliance Test (RRT), a tool designed to help patients self-assess and change their behavior related to SABA usage.
- Results showed that 82% of participants were at medium-to-high risk for SABA over-reliance, 73% reported SABA overuse, and 75% intended to discuss their treatment with a doctor, indicating that the RRT effectively raised awareness and facilitated discussions about asthma management.
Budesonide/Glycopyrrolate/Formoterol for the Management of COPD in a UK Primary Care Population: Real-World Use and Early Medication Success.
Int J Chron Obstruct Pulmon Dis
May 2024
Observational and Pragmatic Research Institute, Singapore, Singapore.
Purpose: Real-life research is needed to evaluate the effectiveness of budesonide/glycopyrrolate/formoterol (BGF) in routine COPD primary care management. We assessed the frequency of medication success among patients with COPD who initiated BGF using real-world data.
Patients And Methods: Patients with a recorded diagnostic COPD code who started BGF with ≥2 prescriptions within 90-days were identified in the UK Optimum Patient Care Research Database and followed from first prescription until censoring at the end of follow-up (180-days), death, leaving database or end of data at 24/10/2022.
Reducing short-acting beta-agonist use in asthma: Impact of national incentives on prescribing practices in England and the findings from SENTINEL Plus early adopter sites.
NPJ Prim Care Respir Med
April 2024
Medical Affairs, AstraZeneca, London, UK.
Short-acting beta-agonist (SABA) over-use in asthma is harmful for patients and the environment. The Investment and Impact Fund (IIF) 2022/2023 financially rewarded English primary care networks that achieved specific targets, including reducing SABA over-use (RESP-02) and lowering the mean carbon footprint per salbutamol inhaler prescribed (ES-02). SENTINEL Plus is a co-designed quality improvement package that aims to improve asthma outcomes and reduce asthma's environmental impact by addressing SABA over-use.
View Article and Find Full Text PDFHigh Use of SABAs is Associated with Higher Exacerbation Rate in Dutch Patients with Asthma.
J Asthma Allergy
July 2021
General Practitioners Research Institute, Groningen, the Netherlands.
Purpose: Many patients with asthma still have insufficient disease control, despite the availability of effective treatment options. A substantial proportion of patients appear to rely more on short-acting beta-agonist (SABA) rather than on anti-inflammatory maintenance treatment. The aim of this study was to describe differences in indicators of asthma symptoms and exacerbations among patients using more or less SABA than the guideline-recommended threshold of <3 times/week.
View Article and Find Full Text PDFEffective Asthma Management: Is It Time to Let the AIR out of SABA?
J Clin Med
March 2020
Division of Allergy & Immunology, Department of Medicine, Queen's University, Kingston K7L 3N6, Ontario, Canada.
For years, standard asthma treatment has included short acting beta agonists (SABA), including as monotherapy in patients with mild asthma symptoms. In the Global Initiative for Asthma 2019 strategy for the management of asthma, the authors recommended a significant departure from the traditional treatments. Short acting beta agonists (SABAs) are no longer recommended as the preferred reliever for patients when they are symptomatic and should not be used at all as monotherapy because of significant safety concerns and poor outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!